Amgen's denosumab shows bone benefit in men
This article was originally published in Scrip
Amgen's denosumab increases bone mineral density and reduces fracture incidence in men undergoing androgen-deprivation therapy (ADT) for prostate cancer, top-line results from a pivotal Phase III study suggest.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
Gilead Scienceswill need to conduct another clinical trial of its investigational cystic fibrosis treatment aztreonam lysine for inhalation before the drug can be approved, the US FDAhas said.